In this study, we developed a novel method for objective phenotyping of CD163+ TAMs and present new spatial metrics of proximity of CD163+ TAMs to cancer cells that are independent predictors of clinical outcome in high-risk breast cancer patients treated with adjuvant chemotherapy. This evidence concerns the gene CD163 and breast cancer.